Brief: Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD

PepGen

04/03/2025 13:18

March 4 (Reuters) - PepGen Inc PEPG.O:

PEPGEN ANNOUNCES UPDATE TO PHASE 2 CONNECT2-EDO51 STUDY IN PATIENTS WITH DMD

PEPGEN INC - TO PAUSE PHASE 2 CONNECT2-EDO51 STUDY IN DMD PATIENTS

PEPGEN INC - DATA FROM 10 MG/KG COHORT EXPECTED IN Q3 2025

PEPGEN INC: WILL FOCUS EFFORTS ON ONGOING CONNECT1-EDO51 STUDY OF PGN-EDO51 IN DMD

PEPGEN INC - NO NEW SAFETY ISSUES OBSERVED IN PGN-EDO51 PROGRAM

Source text: ID:nBw1spcTNa

Further company coverage: PEPG.O

 (Reuters.Briefs@thomsonreuters.com)